{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:32:06Z","timestamp":1777051926459,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/s1470-2045(19)30029-4","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T18:43:18Z","timestamp":1554144198000},"page":"636-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":464,"title":["Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Kathleen N","family":"Moore","sequence":"first","affiliation":[]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[]},{"given":"Melissa A","family":"Geller","sequence":"additional","affiliation":[]},{"given":"David Scott","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Noelle","family":"Cloven","sequence":"additional","affiliation":[]},{"given":"Gini F","family":"Fleming","sequence":"additional","affiliation":[]},{"given":"Andrea E","family":"Wahner Hendrickson","sequence":"additional","affiliation":[]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[]},{"given":"Paul","family":"DiSilvestro","sequence":"additional","affiliation":[]},{"given":"Amit M","family":"Oza","sequence":"additional","affiliation":[]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[]},{"given":"Jonathan S","family":"Berek","sequence":"additional","affiliation":[]},{"given":"John K","family":"Chan","sequence":"additional","affiliation":[]},{"given":"Bobbie J","family":"Rimel","sequence":"additional","affiliation":[]},{"given":"Daniela E","family":"Matei","sequence":"additional","affiliation":[]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[]},{"given":"Kaiming","family":"Sun","sequence":"additional","affiliation":[]},{"given":"Katarina","family":"Luptakova","sequence":"additional","affiliation":[]},{"given":"Ursula A","family":"Matulonis","sequence":"additional","affiliation":[]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(19)30029-4_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Seigel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/S1470-2045(19)30029-4_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2004.07.008","article-title":"Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer","volume":"95","author":"McMeekin","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","article-title":"Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer","volume":"141","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib5","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/cncr.29995","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","volume":"122","author":"Matulonis","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(19)30029-4_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1359-6349(15)70005-4","article-title":"Limitations to the use of carboplatin-based therapy in advanced ovarian cancer","volume":"12","author":"Fotopoulou","year":"2014","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/S1470-2045(19)30029-4_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ygyno.2005.03.022","article-title":"Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer","volume":"97","author":"Hoskins","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2012.10.003","article-title":"Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer","volume":"166","author":"Bruchim","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib9","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(19)30029-4_bib11","doi-asserted-by":"crossref","first-page":"37\u2008080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/S1470-2045(19)30029-4_bib12","doi-asserted-by":"crossref","first-page":"PR05","DOI":"10.1158\/1078-0432.OVCA13-PR05","article-title":"In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer","volume":"19","author":"AlHilli","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(19)30029-4_bib13","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S0959-8049(17)30399-4","article-title":"A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor models","volume":"72","author":"Mikule","year":"2017","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.1016\/S1470-2045(19)30029-4_bib14","doi-asserted-by":"crossref","first-page":"A102","DOI":"10.1158\/1535-7163.TARG-17-A102","article-title":"A comparative pharmacokinetic-pharmacodynamic-treatment study of PARP inhibitors demonstrates favorable properties for niraparib activity in preclinical tumor models","volume":"17","author":"Sun","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/S1470-2045(19)30029-4_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/S1470-2045(19)30029-4_bib16","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(19)30029-4_bib17","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib21","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(19)30029-4_bib22","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(19)30029-4_bib23","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/S1470-2045(19)30029-4_bib24","doi-asserted-by":"crossref","first-page":"e18091","DOI":"10.1200\/JCO.2016.34.15_suppl.e18091","article-title":"Association of clinical benefit rate (CBR) with survival: a pooled-analysis of metastatic breast cancer (MBC) trials submitted to the US Food and Drug Administration (FDA)","volume":"34","author":"Amiri-Kordestani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumour response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib26","first-page":"1233","article-title":"Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients","volume":"15","author":"Cesano","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib27","doi-asserted-by":"crossref","first-page":"1672176","DOI":"10.1155\/2018\/1672176","article-title":"Evaluation of treatment effect with paired failure times in a single-arm phase II trial in oncology","volume":"2018","author":"Texier","year":"2018","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/S1470-2045(19)30029-4_bib28","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumours to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"suppl 8","key":"10.1016\/S1470-2045(19)30029-4_bib30","first-page":"944P","article-title":"QUADRA: a phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset","volume":"29","author":"Moore","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib31","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.28940","article-title":"Patient preferences in advanced or recurrent ovarian cancer","volume":"120","author":"Havrilesky","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(19)30029-4_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","article-title":"Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance","volume":"140","author":"Minion","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib33","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(19)30029-4_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1016\/s1470-2045(19)30242-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000}}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204519300294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204519300294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:23:30Z","timestamp":1761459810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204519300294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1470204519300294"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(19)30029-4","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30087-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}